TMEM161B

Across TCGA pan-cancer cohorts, TMEM161B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM161B data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher TMEM161B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM161B expression acts as an unfavorable survival marker.

KICH, UCEC, and HNSC are the cancer types where TMEM161B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
HNSC	DFS	Median	All	0.132	0.625	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM161B–KICH (DFS)

Open the KICH breakdown →